Favorable Response to Chemotherapy with Durvalumab Plus Tremelimumab in Two Cases of KRAS G12C-positive…

Abstract

Pulmonary sarcomatoid carcinoma (PSC) and Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations are poor prognostic factors in non-small cell lung cancer. We report two cases of metastatic KRAS G12C-positive PSC in men (aged 69 and 66 years). Both patients were treated with chemotherapy combined with durvalumab and tremelimumab (POSEIDON regimen). They thereafter achieved excellent clinical outcomes, including complete and partial responses, with sustained benefits. The POSEIDON regimen may represent a potent therapeutic option for this rare patient population with multiple negative prognostic factors.

An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn – ALICE (PRODIGE89 – UCGI44 – ALICE)
Octave Letissier, Xavier Adhoute, Boris Campillo-Gimenez +21
Digestive and Liver Disease17 Sep 2026Peer-reviewedCC BY-NC-NDFull textGeneral biology OncologyHAL
A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment
Saki Sueda, Tomokazu Kawaoka, Yasutoshi Fujii +7
Internal Medicine19 Aug 2026Peer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
Immune-mediated Myocarditis after Durvalumab/tremelimumab Treatment for Unresectable Hepatocellular Carcinoma
Shogo Mawatari, Ryu Sasaki, Yasuhiko Nakao +4
Internal Medicine1 Oct 2026Peer-reviewedCC BY-NC-NDFull text1 citedOncologyJ-STAGE
An Effective Case of Radiofrequency Ablation with the Combination of Durvalumab and Tremelimumab Treatment for Hepatocellular Carcinoma
Koji Rinka, Kiyohide Kioka, Rika Shioji +16
Internal Medicine1 Oct 2026Peer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
Outcomes by Comorbidities with Tremelimumab and Durvalumab in the Randomized, Controlled Phase 3 HIMALAYA Study in Unresectable Hepatocellular Carcinoma.
Lorenza Rimassa, Farshid Dayyani, Robin K Kelley +6
Liver cancer28 Jul 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeX RIS

BibTeX

@article{ichikawa2026favorable,
  title = {{Favorable Response to Chemotherapy with Durvalumab Plus Tremelimumab in Two Cases of KRAS G12C-positive Pulmonary Sarcomatoid Carcinoma}},
  author = {Takeru Ichikawa and Kenichiro Kudo and Yuki Takigawa and Tomoya Osedo and Yuto Sasano and Toki Kitano and Jun Nishimura and Hiromi Watanabe and Ken Sato and Keiichi Fujiwara},
  journal = {Internal Medicine},
  year = {2026},
  month = oct,
  doi = {10.2169/internalmedicine.6660-25},
  url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/20/65_6660-25/_article},
  note = {CC BY-NC-ND},
}

RIS

TY  - JOUR
TI  - Favorable Response to Chemotherapy with Durvalumab Plus Tremelimumab in Two Cases of KRAS G12C-positive Pulmonary Sarcomatoid Carcinoma
AU  - Takeru Ichikawa
AU  - Kenichiro Kudo
AU  - Yuki Takigawa
AU  - Tomoya Osedo
AU  - Yuto Sasano
AU  - Toki Kitano
AU  - Jun Nishimura
AU  - Hiromi Watanabe
AU  - Ken Sato
AU  - Keiichi Fujiwara
PY  - 2026
DA  - 2026/10/15
JO  - Internal Medicine
DO  - 10.2169/internalmedicine.6660-25
UR  - https://www.jstage.jst.go.jp/article/internalmedicine/65/20/65_6660-25/_article
AB  - Pulmonary sarcomatoid carcinoma (PSC) and Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations are poor prognostic factors in non-small cell lung cancer. We report two cases of metastatic KRAS G12C-positive PSC in men (aged 69 and 66 years). Both patients were treated with chemotherapy combined with durvalumab and tremelimumab (POSEIDON regimen). They thereafter achieved excellent clinical outcomes, including complete and partial responses, with sustained benefits. The POSEIDON regimen may represent a potent therapeutic option for this rare patient population with multiple negative prognostic factors.
SN  - 1349-7235
SN  - 0918-2918
ER  -

Abstract

Related

Cite